Critical revision of the medical treatment of gout in Brazil
Rev Bras Reumatol Engl Ed. 2017 Jul-Aug;57(4):346-355.
doi: 10.1016/j.rbre.2017.03.002.
Epub 2017 Apr 6.
[Article in
English,
Portuguese]
Affiliations
- 1 Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Clinica Médica, Curitiba, PR, Brazil. Electronic address: [email protected].
- 2 Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Clinica Médica, Curitiba, PR, Brazil.
- 3 Universidade do Estado do Rio de Janeiro, Serviço de Reumatologia, Rio de Janeiro, RJ, Brazil.
Abstract
Gout is considered the most common form of inflammatory arthritis in men over 40 years. The authors present a brief review of the current treatment of gout and discuss the existing pharmacological limitations in Brazil for the treatment of this disease. Although allopurinol is still the main drug administered for decreasing serum levels of uric acid in gout patients in this country, the authors also present data that show a great opportunity for the Brazilian drug market for the treatment of hyperuricemia and gout and especially for patients using private and public (SUS) health care systems.
Keywords:
Artrite gotosa; Gota; Gout; Gouty arthritis; Hiperuricemia; Hyperuricaemia; Medicamentos; Medicines; Tratamento; Treatment.
Copyright © 2017 Elsevier Editora Ltda. All rights reserved.
MeSH terms
-
Brazil / epidemiology
-
Drug Approval
-
Gout / blood
-
Gout / drug therapy*
-
Gout / epidemiology
-
Gout Suppressants / therapeutic use*
-
Humans
-
Hyperuricemia / blood
-
Hyperuricemia / drug therapy*
-
Hyperuricemia / epidemiology
-
Incidence
-
Uric Acid / blood*
Substances
-
Gout Suppressants
-
Uric Acid